Skip to main content
Clinical Trials/NCT03557229
NCT03557229
Unknown
Phase 3

Randomized Controlled Clinical Trial of Antioxidant Therapy in Critically Ill Patients With Septic Shock: Analysis Before and After Treatment of the Oxidative Stress

American British Cowdray Medical Center1 site in 1 country131 target enrollmentJuly 23, 2018

Overview

Phase
Phase 3
Intervention
Melatonin 5 mg
Conditions
Oxidative Stress
Sponsor
American British Cowdray Medical Center
Enrollment
131
Locations
1
Primary Endpoint
Organic failure measurement by the Sequential Organ Failure Assessment Score (SOFA)
Last Updated
4 years ago

Overview

Brief Summary

Sepsis and septic shock are public health problems worldwide that represents an excessive cost for health systems. Despite the great technological and research advances, mortality can reach up to 80% in patients with multiple organ failure (FOM). Therapeutic studies focused on evaluating the usefulness of the use of antioxidants have shown different outcomes and results. This randomized clinical trial in patients with septic shock at two general intensive care units try to evaluate the usefulness of four different antioxidant therapies added to the conventional treatment, which includes: n-acetyl cysteine, vitamin C, vitamin E and melatonin. Measurement of parameters before and after treatment of oxidative stress includes nitrates and nitrites, lipid peroxidation, glutathione peroxidase, glutathione s transferase, extracellular activity of SOD, GSH concentration and evaluation of total antioxidant capacity. The investigators will also evaluate the clinical impact of antioxidant therapy with the SOFA score.

Registry
clinicaltrials.gov
Start Date
July 23, 2018
End Date
June 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
American British Cowdray Medical Center
Responsible Party
Principal Investigator
Principal Investigator

Alfredo Aisa Alvarez

Principal Investigator

American British Cowdray Medical Center

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of septic shock in the last 24 hours characterized by refractory hypotension and vasopressor requirement despite sufficient fluid resuscitation (20 mL/kg of colloids or 40 mL/kg of crystalloids) to maintain a blood pressure ≥ 65 mmHg with a lactate\> 2 mmol/L.
  • Admitted to the ICU of the ABC Medical Center.
  • Give informed consent.

Exclusion Criteria

  • Patients who refuse to be included.
  • Chronic or recent use of steroids.
  • Use of statins.
  • Patients receiving some type of antioxidant treatment.
  • Any contraindication to the use of vitamin C, vitamin E, n-acetylcysteine or melatonin.
  • Pregnant women.

Arms & Interventions

Melatonin

Intervention: Melatonin 5 mg

Vitamin C

Intervention: Vitamin C 1 GM Oral Tablet

Vitamin E

Intervention: Vitamin E 400 UNT

N-acetylcysteine

Intervention: N-acetylcysteine

Outcomes

Primary Outcomes

Organic failure measurement by the Sequential Organ Failure Assessment Score (SOFA)

Time Frame: Up to 7 days (1 week). From date of randomization and every 24 hours until discharge from the intensive care unit or date of death from any cause, whichever came first, assessed up to 7 days.

The SOFA score is used to track a person's status during the stay in an intensive care unit (ICU) to determine the extent of a person's organ function or rate of failure. The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure). The worst physiological variables is collected serially every 24 hours of a patient's ICU admission. The "worst" measurement is defined as the measure that correlated to the highest number of points. The SOFA score ranges from 0 to 24. The investigators are going to evaluate the daily total score and the trend before and after the administration of the therapy.

Secondary Outcomes

  • Nitrates and nitrites levels(Immediately before treatment and 48 hours after therapy)
  • Malondialdehyde levels(Immediately before treatment and 48 hours after therapy)
  • Glutathione Peroxidase Enzyme Activity(Immediately before treatment and 48 hours after therapy)
  • Carbonylation(Immediately before treatment and 48 hours after therapy)
  • Total antioxidant capacity(Immediately before treatment and 48 hours after therapy)
  • Glutathione S-transferase Activity(Immediately before treatment and 48 hours after therapy)
  • Extracellular Superoxide Dismutase Activity(Immediately before treatment and 48 hours after therapy)
  • Glutathione concentration(Immediately before treatment and 48 hours after therapy)
  • Selenium(Immediately before treatment and 48 hours after therapy)
  • Vitamin C(Immediately before treatment and 48 hours after therapy)
  • Thioredoxin(Immediately before treatment and 48 hours after therapy)

Study Sites (1)

Loading locations...

Similar Trials